CurrentViva Health PlanPolicy IC-0207

Ruconest (C1 Esterase Inhibitor [recombinant]) Intravenous Therapy for Acute Hereditary Angioedema Attacks

Customize your policy alerts

Sign up for vivahealthplan Policy IC-0207 alerts

Get alerted when Policy IC-0207 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs prior authorization, dosing, quantity limits, and coverage criteria for intravenous Ruconest used to treat acute hereditary angioedema attacks in Viva Health Plan commercial members age 13 years and older who meet specified specialist, safety, diagnostic, and clinical criteria.

Policy Summary

PayerViva Health Plan

PolicyRuconest intravenous therapy for acute hereditary angioedema attacks

Policy CodePolicy IC-0207

Change TypeNo material clinical or coverage change

Effective DateN/A

Last ReviewOct 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization for members age 13 years or older who meet the applicable clinical criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

13+Minimum age

12 weeksAuthorization period

4 attacksSupply limit

3360 unitsMaximum quantity

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentViva Health PlanPolicy IC-0207

Ruconest (C1 Esterase Inhibitor [recombinant]) Intravenous Therapy for Acute Hereditary Angioedema Attacks

Customize your policy alerts

Sign up for vivahealthplan Policy IC-0207 alerts

Get alerted when Policy IC-0207 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerViva Health Plan

PolicyRuconest intravenous therapy for acute hereditary angioedema attacks

Policy CodePolicy IC-0207

Change TypeNo material clinical or coverage change

Effective DateN/A

Last ReviewOct 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization for members age 13 years or older who meet the applicable clinical criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

13+Minimum age

12 weeksAuthorization period

4 attacksSupply limit

3360 unitsMaximum quantity

2 doses24-hour frequency

Coverage Criteria

Initial Therapy – Acute HAE Attack

Covered for initial treatment of an acute hereditary angioedema attack when ALL applicable criteria are met:

ALL of the following

Member is at least 13 years of age.
Requested agent is prescribed by, or in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics.
Provider confirms that the member has been counseled to avoid possible medication triggers for HAE attacks, including estrogen-containing medications and ACE inhibitors.
Member has a history of ONE or more of the following:
- Recurrent swelling of mucous membranes, skin surface, or subcutaneous tissue.
- Recurrent abdominal attacks with severe abdominal pain, nausea, vomiting, or diarrhea.
- Episodes of upper-airway edema, including mouth, tongue, or laryngeal edema.
- Prodromal signs or symptoms preceding angioedema attacks, such as anxiety, nausea, paresthesia, or fatigue.
- Positive family history of HAE.
Diagnosis of HAE is confirmed by ONE of the following pathways:
- HAE due to C1-inhibitor deficiency (HAE-C1-INH) Type 1 or 2:
  - At least ONE confirming finding:
    Current or historical C1-INH antigenic level is below the lower limit of normal as defined by the laboratory performing the test.
    Current or historical C1-INH functional level is below the lower limit of normal as defined by the laboratory performing the test.
    Genetic testing confirms pathogenic mutation(s) in SERPING1.
- HAE with normal C1-INH (HAE-nC1-INH):
  - Current or historical C1-INH level is normal as defined by the laboratory performing the test.
  - At least ONE confirming finding:

Continuation Therapy

Continuation therapy is covered when ALL of the following criteria are met:

ALL of the following

Member continues to meet the universal and other indication-specific applicable criteria identified for initial therapy.
Member has experienced clinical benefit from therapy, such as reduced attack severity or shortened attack duration.
Member has no unacceptable toxicity from the drug, including severe hypersensitivity reactions (including anaphylaxis) or serious arterial or venous thromboembolic events.
The cumulative amount of medication(s) the member has on hand for acute HAE treatment is considered when authorization is determined.
The authorization provides a sufficient quantity for the member to have a cumulative amount of HAE medication(s) on hand to treat up to 4 acute attacks per 4 weeks for the duration of the authorization.

Coverage is not provided when the member has an FDA-labeled contraindication to Ruconest, including a known or suspected allergy to rabbits or rabbit-derived products, or a history of immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations.

Ruconest must not be used in combination with another agent indicated for the treatment of acute hereditary angioedema attacks. Requests for combination duplicate therapy may be appropriate in some situations and will be reviewed on a case-by-case basis.

Coverage is excluded when other causes of angioedema have not been ruled out, including drug-induced angioedema, mast cell-mediated angioedema, or acquired angioedema due to C1-INH deficiency. Coverage is also excluded when the applicable clinical history, diagnostic confirmation, specialist involvement, counseling, age, benefit, toxicity, or quantity requirements are not met.

Coding and Dose Parameters

HCPCS CodeHCPCSCovered

J0596

Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units

NDCNDCCovered

71274-0350-xx

Ruconest 2100 U single-use 25 mL vial

Covered Diagnosis CodesICD-10Covered

D84.1

Defects in the complement system

Covered Diagnosis CodesICD-10Covered

D84.1

Defects in the complement system

Coding Limit

Maximum quantity3360 billable units

Billing unitHCPCS billable units

Limit periodPer 28 days

Age Requirement

Minimum member age13 years

Applies toInitial approval

Eligibility requirement

Authorization and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Initial authorization is valid for 12 weeks and is available only when the member is at least 13 years of age and the universal and indication-specific criteria are met.

Authorization may be renewed every 12 weeks thereafter.
The request must satisfy the specialist, contraindication, duplicate-therapy, counseling, HAE history, diagnostic, and alternative-diagnosis requirements below.

Billing Rule

Coordinate Cumulative HAE Supply

Authorization must account for the member’s cumulative on-hand supply of medications indicated for acute HAE treatment. Approve only a quantity sufficient for the member to have enough medication to treat up to 4 acute attacks per 4 weeks for the duration of the authorization.

Clinical Background

Hereditary angioedema (HAE) is characterized by recurrent episodes of swelling involving the skin, mucous membranes, subcutaneous tissues, abdomen, or upper airway. Ruconest is recombinant C1 esterase inhibitor administered by intravenous injection for treatment of acute HAE attacks.

Definitions and Diagnosis

HAE-C1-INH

DefinitionHereditary angioedema due to C1 inhibitor deficiency

Types includedType 1 or Type 2

ConfirmationLow C1-INH antigenic or functional level below the laboratory lower limit of normal, or a pathogenic SERPING1 mutation

HAE-nC1-INH

DefinitionHereditary angioedema with normal C1 inhibitor

Laboratory findingCurrent or historical normal C1-INH level

Supporting evidenceA known HAE-causing mutation in F12, ANGPT1, PLG, KNG1, MYOF, or HS3ST6, or recurrent angioedema attacks without hives refractory to a four-week trial of high-dose antihistamines

Initial Treatment of Acute HAE

Initial authorization is available for members age 13 years and older when all universal criteria and one covered acute HAE diagnostic pathway are satisfied.

Initial Ruconest criteria

Member is at least 13 years of age.Age >=13 years
Universal criteria
- Treatment is prescribed by, or provided in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics.
- Member does not have an FDA-labeled contraindication, including known or suspected allergy to rabbits or rabbit-derived products or a history of immediate hypersensitivity reaction, including anaphylaxis, to C1 esterase inhibitor preparations.

Ruconest Renewal

Renewal is available every 12 weeks when all continuation requirements are met.

Ruconest renewal

Member continues to meet the universal and other indication-specific relevant criteria identified for initial approval.
Member has experienced clinical benefit from therapy, such as reduced attack severity or shortened attack duration.
Member has no unacceptable toxicity from Ruconest, including severe hypersensitivity reactions such as anaphylaxis or serious arterial or venous thromboembolic events.
The member's cumulative on-hand supply of medications indicated for acute HAE treatment is considered when authorizing, with sufficient quantity to maintain a cumulative supply capable of treating up to four acute attacks per four weeks for the duration of the authorization.Every 12 weeks

Quantity and Supply Limits

Ruconest Quantity Limit

DrugRuconest

Maximum quantity3360 billable units

Limit periodPer 28 days

Acute HAE Medication Supply

Medication supplyRuconest and other acute HAE medications

Cumulative on-hand supplySufficient to treat up to 4 acute attacks

Supply periodPer 4 weeks during the authorization period

Administration Site and Method

Billing Rule

Administer in the office by IV injection

Administer Ruconest by intravenous injection in the office setting.

For body weight below 84 kg, the dose is 50 U/kg by intravenous injection.
For body weight of at least 84 kg, administer 4200 U by intravenous injection.

Policy Summary

PayerViva Health Plan

PolicyRuconest intravenous therapy for acute hereditary angioedema attacks

Policy CodePolicy IC-0207

Change TypeNo material clinical or coverage change

Effective DateN/A

Last ReviewOct 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization for members age 13 years or older who meet the applicable clinical criteria.

SourceLink

On This Page

Known HAE-causing mutation(s) are confirmed in F12, ANGPT1, PLG, KNG1, MYOF, and/or HS3ST6.
Recurrent angioedema attacks without hives are refractory to a 4-week trial of high-dose antihistamines, defined as a second-generation H1 antagonist at four times the standard dose.

Member must be at least 13 years of age

Weight-Based Dose

Body weight below 84 kg50 U/kg by intravenous injection

Body weight at or above 84 kg4200 U by intravenous injection

Administration routeIntravenous injection

Dose Limit

Maximum dose4200 U per dose

Applies toTreatment of an acute hereditary angioedema attack

Dose restrictionDo not exceed 4200 U per dose

Frequency Limit

Maximum frequencyNo more than two doses within a 24-hour period

Additional doseA second dose may be administered if attack symptoms persist

Dose levelAdminister the additional dose at the recommended dose level

Apply the cumulative on-hand supply adjustment at both initial authorization and renewal.
Do not authorize quantities without considering other acute HAE medication already available to the member.

Documentation Required

Universal Clinical Documentation

Documentation must establish specialist involvement, review of FDA-labeled contraindications, appropriate use without duplicate acute-HAE therapy, and counseling regarding potential HAE medication triggers.

Ruconest must be prescribed by, or used in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics.
Document that the member does not have a labeled contraindication, including known or suspected allergy to rabbits or rabbit-derived products or prior immediate hypersensitivity, including anaphylaxis, to C1 esterase inhibitor preparations.
Document that Ruconest will not be used with another agent indicated for acute HAE attacks. Combination duplicate therapy may be reviewed case by case.
Confirm counseling to avoid possible medication triggers, such as estrogen-containing medications and ACE inhibitors.
Document that other causes of angioedema have been ruled out, including drug-induced, mast cell-mediated, and acquired angioedema due to C1-INH deficiency.

Unsupported block type: documentation

Documentation Required

Renewal Documentation Required

Renewal requires continued fulfillment of the universal and relevant indication-specific criteria, documented clinical benefit, and acceptable safety and utilization.

Document clinical benefit, such as reduced attack severity or shortened attack duration.
Document absence of unacceptable toxicity, including severe hypersensitivity reactions or serious arterial or venous thromboembolic events.
Reassess the member’s cumulative on-hand acute-HAE medication supply when determining the renewal quantity.

Denial Risk

Initial Approval Denial Conditions

Initial authorization should be denied when the member does not meet the age requirement or any applicable universal or HAE-specific clinical criteria.

Deny when the member is younger than 13 years of age.
Deny when required specialist involvement, contraindication review, trigger counseling, duplicate-therapy assessment, or alternative-diagnosis exclusion is not documented or is not met.
Deny when the member lacks qualifying recurrent swelling, abdominal, airway, prodromal, or family-history evidence and the required HAE diagnostic confirmation.
Deny when the requested indication does not meet the applicable HAE-C1-INH, HAE-nC1-INH, genetic, or antihistamine-refractory criteria.

Denial Risk

Renewal Denial Conditions

Renewal should be denied when continued criteria are not met, the therapy has not provided clinical benefit, unacceptable toxicity is present, or utilization cannot be supported within the authorization limits.

Deny when the member no longer meets the universal or applicable indication-specific criteria.
Deny for lack of documented clinical benefit, such as no reduction in attack severity or duration.
Deny for unacceptable toxicity, including severe hypersensitivity or serious arterial or venous thromboembolic events.
Deny or reduce renewal when cumulative on-hand supply or requested utilization exceeds the quantity needed to treat up to 4 acute attacks per 4 weeks.

Billing Rule

Excess Quantity or Dosing

Claims and authorizations are subject to dose, frequency, quantity, and authorization-supply limits. Excess units or dosing may be denied or may affect claim payment.

Maximum: 3360 billable units per 28 days.
For an acute HAE attack, administer 50 U/kg intravenously when body weight is less than 84 kg.
For body weight of 84 kg or more, administer 4200 U (2 vials) intravenously.
If symptoms persist, a second dose at the recommended dose level may be administered; do not exceed 4200 U per dose.
Do not administer more than two doses within any 24-hour period.
Do not exceed the authorized cumulative supply, quantity, dose, or frequency limits; excess billing may be denied.

Covered Diagnosis

ICD-10 codeD84.1

DefinitionDefects in the complement system

Code systemICD-10

Ruconest will not be used with another agent indicated for treatment of acute HAE attacks, unless duplicate therapy is determined appropriate through case-by-case review.

Provider confirms counseling to avoid possible HAE medication triggers, including estrogen-containing medications and ACE inhibitors.

Covered acute HAE diagnostic pathway

HAE-C1-INH Type 1 or 2
- Member has a qualifying history of recurrent swelling, recurrent abdominal attacks, upper-airway edema, prodromal signs or symptoms, or a positive family history of HAE.
- Other causes of angioedema have been ruled out.
- Diagnostic confirmation
  - Current or historical C1-INH antigenic level is below the laboratory lower limit of normal.
  - Current or historical C1-INH functional level is below the laboratory lower limit of normal.
  - Genetic testing confirms pathogenic mutation(s) in SERPING1.
HAE with normal C1-INH
- Member has a qualifying HAE history and other causes of angioedema have been ruled out.
- Member has a current or historical normal C1-INH level.
- Diagnostic confirmation
  - Known HAE-causing mutation is confirmed in F12, ANGPT1, PLG, KNG1, MYOF, or HS3ST6.
  - Member has recurrent angioedema attacks without hives refractory to a four-week trial of high-dose second-generation H1 antagonist therapy.Four weeks; high dose = four times the standard dose